Completed PHASE2 INTERVENTIONAL 2-arm NCT01796028

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer (TAXOMET)

A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE®+Metformine Placebo Versus TAXOTERE®+Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.

Sponsor: Centre Antoine Lacassagne

Conditions Prostatic Neoplasms

Interventions METFORMIN Placebo TAXOTERE®

Updated 6 times since 2017 Last updated: Jun 4, 2018 Started: Jan 31, 2013 Primary completion: Dec 31, 2015 Completion: May 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prostatic Neoplasms and is currently completed. Centre Antoine Lacassagne leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Antoine Lacassagne

Data source: Centre Antoine Lacassagne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nice, France